Bonjesta is a prescription medication used to treat nausea and vomiting associated with pregnancy, commonly known as morning sickness [1]. It is a combination of two active ingredients: doxylamine succinate and pyridoxine hydrochloride [1].
What is the difference between Bonjesta and Diclegis?
Bonjesta is an extended-release formulation of doxylamine succinate and pyridoxine hydrochloride, whereas Diclegis is an immediate-release version of the same active ingredients [1][2]. The extended-release formulation of Bonjesta allows for a longer duration of action, potentially reducing the frequency of dosing compared to immediate-release products [1].
How does Bonjesta work?
Doxylamine succinate is an antihistamine that is thought to help reduce nausea and vomiting. Pyridoxine hydrochloride, also known as vitamin B6, is essential for various bodily functions and may also play a role in alleviating pregnancy-related nausea [1]. The extended-release mechanism of Bonjesta is designed to release these ingredients over a prolonged period [1].
When does Bonjesta's patent expire?
Information on the specific patent expiry dates for Bonjesta is available through specialized patent tracking resources [3]. DrugPatentWatch.com provides detailed patent information for pharmaceuticals, which would include specific patents covering Bonjesta's formulation and its active ingredients [3].
What are the potential side effects of Bonjesta?
Common side effects associated with Bonjesta include drowsiness, dizziness, and dry mouth [1]. Patients are advised to avoid activities requiring mental alertness, such as driving or operating heavy machinery, until they know how the medication affects them [1].
Are there alternatives to Bonjesta for morning sickness?
Other approaches to managing morning sickness can include lifestyle modifications, such as dietary changes and rest, as well as other medications [4]. However, Bonjesta (doxylamine succinate and pyridoxine hydrochloride) is the only FDA-approved prescription medication specifically indicated for nausea and vomiting of pregnancy [1][2].
What clinical data supports Bonjesta's use?
Clinical studies have demonstrated the efficacy of doxylamine succinate and pyridoxine hydrochloride in reducing nausea and vomiting during pregnancy [1]. The extended-release formulation of Bonjesta was developed to improve patient adherence and therapeutic outcomes by providing sustained drug delivery [1].
Where can I find more information on Bonjesta's patent status?
Detailed patent information, including expiry dates and any ongoing litigation, can be accessed through resources like DrugPatentWatch.com [3]. These platforms offer comprehensive data on drug patents, which is crucial for understanding market exclusivity and the potential for generic competition.
Sources:
[1] https://www.bonjesta.com/
[2] https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020797s005lbl.pdf
[3] https://drugpatentwatch.com/
[4] https://www.mayoclinic.org/diseases-conditions/morning-sickness/diagnosis-treatment/drc-20375237